

# Alexander A Vinks

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9203892/publications.pdf>

Version: 2024-02-01

169  
papers

5,744  
citations

94433

37  
h-index

91884

69  
g-index

175  
all docs

175  
docs citations

175  
times ranked

6676  
citing authors

#	ARTICLE	IF	CITATIONS
1	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 498-509.	9.1	745
2	Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. <i>Pediatrics</i> , 2016, 137, e20153257.	2.1	569
3	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 261-307.	2.0	374
4	Ecuzumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 518-525.	2.0	218
5	Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. <i>Clinical Transplantation</i> , 2008, 22, 281-291.	1.6	157
6	Variable Ecuzumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 307-315.	2.0	125
7	Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. <i>Oncologist</i> , 2018, 23, 52-61.	3.7	123
8	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. <i>Neuro-Oncology</i> , 2015, 17, 596-603.	1.2	118
9	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. <i>Transplantation Reviews</i> , 2011, 25, 47-57.	2.9	116
10	<i>OCT1</i> genetic variants influence the pharmacokinetics of morphine in children. <i>Pharmacogenomics</i> , 2013, 14, 1141-1151.	1.3	85
11	Assessment of tacrolimus inpatient variability in stable adherent transplant recipients: Establishing baseline values. <i>American Journal of Transplantation</i> , 2019, 19, 1410-1420.	4.7	79
12	Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. <i>American Journal of Transplantation</i> , 2019, 19, 2944-2948.	4.7	77
13	Sirolimus for non-progressive NF1-associated plexiform neurofibromas: An NF clinical trials consortium phase II study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 982-986.	1.5	73
14	<i>ABCC3</i> and <i>OCT1</i> genotypes influence pharmacokinetics of morphine in children. <i>Pharmacogenomics</i> , 2014, 15, 1297-1309.	1.3	68
15	Concentration-Effect Relationship of Ceftazidime Explains Why the Time above the MIC Is 40 Percent for a Static Effect In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3449-3451.	3.2	67
16	Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 223-230.	2.5	63
17	Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26470.	1.5	58
18	Morphine clearance in children: Does race or genetics matter?. <i>Journal of Opioid Management</i> , 2012, 8, 217-226.	0.5	58

#	ARTICLE	IF	CITATIONS
19	Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 309-320.	2.0	55
20	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametininb (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , 2021, 39, 797-806.	1.6	54
21	Propofol Clearance in Morbidly Obese Children and Adolescents. <i>Clinical Pharmacokinetics</i> , 2012, 51, 543-551.	3.5	53
22	Developmental Changes in Morphine Clearance Across the Entire Paediatric Age Range are Best Described by a Bodyweight-Dependent Exponent Model. <i>Clinical Drug Investigation</i> , 2013, 33, 523-534.	2.2	52
23	Recommendations for the design of therapeutic trials for neonatal seizures. <i>Pediatric Research</i> , 2019, 85, 943-954.	2.3	52
24	Population Pharmacokinetic Analysis of Nonlinear Behavior of Piperacillin during Intermittent or Continuous Infusion in Patients with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 541-547.	3.2	51
25	Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. <i>American Journal of Hematology</i> , 2019, 94, 871-879.	4.1	51
26	Pharmacokinetics of Aztreonam in Healthy Subjects and Patients with Cystic Fibrosis and Evaluation of Dose-Exposure Relationships Using Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3049-3055.	3.2	50
27	The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease. <i>Clinical Pharmacokinetics</i> , 2011, 50, 1-24.	3.5	50
28	Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 718-724.	2.0	50
29	A Pilot Randomized, Controlled, Double-blind Trial of Bumetanide to Treat Neonatal Seizures. <i>Annals of Neurology</i> , 2021, 89, 327-340.	5.3	50
30	Implementation of Pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons Learned Over 14 Years of Personalizing Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 49-52.	4.7	48
31	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. <i>Neuro-Oncology</i> , 2020, 22, 1527-1535.	1.2	45
32	Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 727-740.	2.4	42
33	Current Management of Neonatal Abstinence Syndrome Secondary to Intrauterine Opioid Exposure. <i>Journal of Pediatrics</i> , 2014, 165, 440-446.	1.8	42
34	Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. <i>Journal of Pediatrics</i> , 2015, 167, 1214-1220.e3.	1.8	42
35	<i>CYP2D6</i> genetic variants are associated with postoperative morphine-related adverse effects in children. <i>Pharmacogenomics</i> , 2017, 18, 621-629.	1.3	42
36	<i>CYP2D6</i> pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. <i>Pharmacogenomics</i> , 2017, 18, 337-348.	1.3	41

#	ARTICLE	IF	CITATIONS
37	Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 761-768.	4.7	41
38	Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S124-S131.	4.0	39
39	Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1639-1647.	4.7	38
40	Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 482-486.	2.0	37
41	The application of population pharmacokinetic modeling to individualized antibiotic therapy. <i>International Journal of Antimicrobial Agents</i> , 2002, 19, 313-322.	2.5	36
42	Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 429-439.	1.9	36
43	Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 742-752.	2.4	35
44	PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 464-473.	2.5	33
45	Electronic Health Record-Embedded Decision Support Platform for Morphine Precision Dosing in Neonates. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 186-194.	4.7	33
46	MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-infusion Care and Use of Glucarpidase. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 635-643.	4.7	32
47	Evaluation of propofol anesthesia in morbidly obese children and adolescents. <i>BMC Anesthesiology</i> , 2013, 13, 8.	1.8	30
48	A Theoretical Physiologically-Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 273-284.	2.5	30
49	Development and Implementation of Electronic Health Record-Integrated Model-Informed Clinical Decision Support Tools for the Precision Dosing of Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 129-135.	4.7	29
50	Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. <i>PLoS Medicine</i> , 2017, 14, e1002428.	8.4	29
51	Population Pharmacokinetics of Sirolimus in Pediatric Patients With Neurofibromatosis Type 1. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 332-337.	2.0	27
52	ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and morphine pharmacokinetics in children. <i>Pharmacogenomics Journal</i> , 2017, 17, 162-169.	2.0	27
53	Measuring Medication Adherence in Pediatric Cancer: An Approach to Validation. <i>Journal of Pediatric Psychology</i> , 2017, 42, 232-244.	2.1	27
54	Pharmacokinetics of IGF-1 in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4568-4577.	3.6	27

#	ARTICLE	IF	CITATIONS
55	The impact of <i>CYP3A5</i> * <i>3</i> polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1438-1446.	2.4	26
56	Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents. <i>Paediatric Anaesthesia</i> , 2015, 25, 911-923.	1.1	24
57	Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 635-641.	2.0	24
58	Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27618.	1.5	24
59	Sirolimus Treatment in Sturge-Weber Syndrome. <i>Pediatric Neurology</i> , 2021, 115, 29-40.	2.1	24
60	Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 38-47.	2.1	23
61	Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy. <i>Clinical Transplantation</i> , 2017, 31, e12975.	1.6	23
62	Learning Health Systems as Facilitators of Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 359-367.	4.7	22
63	Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 168-176.	2.0	22
64	Antibodies to infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 593-603.	3.7	22
65	Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 291-297.	2.0	21
66	Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1418-1426.	2.4	21
67	Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of $\beta$ -Lactam Antibiotics in Critically Ill Children. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 565-573.	2.0	21
68	A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. <i>Clinical Cancer Research</i> , 2015, 21, 1558-1565.	7.0	20
69	Safety and Dose Escalation Study of Intravenous Zinc Supplementation in Pediatric Critical Illness. <i>Journal of Parenteral and Enteral Nutrition</i> , 2016, 40, 860-868.	2.6	20
70	Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1102-1112.	2.4	19
71	Validation of a Pediatric Population Pharmacokinetic Model for Vancomycin. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 413-416.	2.0	19
72	Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. <i>PLoS ONE</i> , 2016, 11, e0146563.	2.5	19

#	ARTICLE	IF	CITATIONS
73	Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to Children. <i>Drug Metabolism and Disposition</i> , 2017, 45, 23-26.	3.3	19
74	A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2220-2225.	2.0	18
75	Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK Observations. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 237-250.	2.5	18
76	Propofol Clearance in Morbidly Obese Children and Adolescents. <i>Clinical Pharmacokinetics</i> , 2012, 51, 543-551.	3.5	18
77	Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugs. <i>Pediatric Transplantation</i> , 2017, 21, e13033.	1.0	17
78	Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Serum Creatinine-Defined Acute Kidney Injury in Infants After Cardiac Surgery. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 186-194.	2.0	17
79	A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28787.	1.5	17
80	Drug Dosing in Obese Children. <i>Pediatric Clinics of North America</i> , 2017, 64, 1417-1438.	1.8	16
81	Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pan-cellular expression of fetal haemoglobin in children with sickle cell anaemia. <i>British Journal of Haematology</i> , 2021, 194, 617-625.	2.5	16
82	Retrospective Evaluation of Milrinone Pharmacokinetics in Children With Kidney Injury. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 792-796.	2.0	15
83	Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 857-870.	2.0	15
84	Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS. <i>Journal of Visualized Experiments</i> , 2015, , e52424.	0.3	15
85	Obesity and overweight as CAE comorbidities and differential drug response modifiers. <i>Neurology</i> , 2016, 86, 1613-1621.	1.1	14
86	Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1097-1107.	2.4	14
87	Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 254-260.	3.0	14
88	NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. <i>Neuro-Oncology</i> , 2018, 20, i143-i143.	1.2	14
89	Milrinone Dosing Issues in Critically Ill Children With Kidney Injury. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 175-181.	1.9	13
90	Precision Medicine "Nobody Is Average. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 304-307.	4.7	13

#	ARTICLE	IF	CITATIONS
91	Intermediate term thrombotic risk in contemporary total cavo-pulmonary connection for single ventricle circulations. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 275-280.	2.1	13
92	Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 128, 209-214.	4.0	13
93	Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1207-1217.	3.5	12
94	Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and postoperative opioid outcomes in children. <i>Pharmacogenomics</i> , 2017, 18, 143-156.	1.3	11
95	Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Pharmacokinetics</i> , 2018, 57, 625-636.	3.5	11
96	Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. <i>Trials</i> , 2020, 21, 983.	1.6	11
97	Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 992-998.	2.0	11
98	Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). <i>Journal of Pediatrics</i> , 2020, 222, 236-239.	1.8	11
99	Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion. <i>Cardiology Research</i> , 2020, 11, 294-304.	1.1	11
100	Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 496-508.	4.7	11
101	A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome. , 2022, 234, 108045.		11
102	Age-Dependent Changes in Sirolimus Metabolite Formation in Patients With Neurofibromatosis Type 1. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 395-399.	2.0	10
103	Model-Informed Bayesian Estimation Improves the Prediction of Morphine Exposure in Neonates and Infants. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 778-786.	2.0	10
104	Precision Dosing: The Clinical Pharmacology of Goldilocks. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 11-14.	4.7	10
105	Population Pharmacokinetic Modeling of Total and Free Ceftriaxone in Critically Ill Children and Young Adults and Monte Carlo Simulations Support Twice Daily Dosing for Target Attainment. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0142721.	3.2	10
106	Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. <i>Blood Advances</i> , 2022, 6, 1454-1463.	5.2	10
107	Pharmacokinetics and Safety of Single-Dose Inhaled Loxapine in Children and Adolescents. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1244-1257.	2.0	9
108	Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery. <i>Clinical Pharmacokinetics</i> , 2019, 58, 793-803.	3.5	9

#	ARTICLE	IF	CITATIONS
109	Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 933-943.	2.4	9
110	Machine Learning as a Novel Method to Support Therapeutic Drug Management and Precision Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 273-276.	4.7	9
111	Methodologic Progress Note: Opportunistic Sampling for Pharmacology Studies in Hospitalized Children. <i>Journal of Hospital Medicine</i> , 2020, 16, 35-37.	1.4	9
112	Important Role of Population Pharmacokinetic/Pharmacodynamic Modeling in Pediatric Therapeutics. <i>Journal of Pediatrics</i> , 2011, 159, 361-363.	1.8	8
113	A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1829-1835.	2.0	8
114	Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , 2017, 56, 107-125.	3.5	8
115	Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 589-604.	2.6	8
116	Status Toward the Implementation of Precision Dosing in Children. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S36-S51.	2.0	8
117	Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	2.4	8
118	Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS <sub>2</sub> -Modified Electrodes and Chemometrics. <i>Biomedicines</i> , 2021, 9, 6.	3.2	8
119	Pharmacokinetics and pharmacogenomics of $\beta$ -lactam-induced neutropenia. <i>Pharmacogenomics</i> , 2016, 17, 547-559.	1.3	7
120	Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 24 months to 24 years of age with urea cycle disorders. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 251-257.	1.1	7
121	Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2416-2421.	2.0	7
122	Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 453-465.	2.0	7
123	Molecular Adsorbent Recirculating System Therapy with Continuous Renal Replacement Therapy Enhanced Clearance of Piperacillin in a Pediatric Patient and Led to Failure to Attain Pharmacodynamic Targets. <i>Pharmacotherapy</i> , 2020, 40, 1061-1068.	2.6	7
124	Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 87-103.	3.3	7
125	Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome. <i>Clinical Pharmacokinetics</i> , 2021, 60, 249-259.	3.5	7
126	Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2923-2931.	3.0	7



#	ARTICLE	IF	CITATIONS
127	A Phase I Trial Of Zileuton In Sickle Cell Disease. <i>Blood</i> , 2013, 122, 993-993.	1.4	7
128	PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing. <i>Frontiers in Pharmacology</i> , 2020, 11, 605060.	3.5	7
129	Therapeutic Optimization as Part of the Precision Medicine Paradigm. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 340-342.	4.7	6
130	Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1651-1658.	3.0	6
131	Opportunities for model-based precision dosing in the treatment of sickle cell anemia. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 143-147.	1.4	5
132	Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial. <i>Intensive Care Medicine</i> , 2018, 44, 2006-2008.	8.2	5
133	Paperspray Ionization Mass Spectrometry as a Tool for Predicting Real-Time Optimized Dosing of the Chemotherapeutic Drug Melphalan. <i>Journal of Applied Laboratory Medicine</i> , 2021, 6, 625-636.	1.3	5
134	Testâ€ dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for nonâ€ malignant disorders. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 115-127.	2.4	5
135	A prospective pilot study of a novel alemtuzumab target concentration intervention strategy. <i>Bone Marrow Transplantation</i> , 2021, 56, 3029-3031.	2.4	5
136	Route of Oseltamivir Administration Affects Metabolite Concentrations in Critically Ill Children. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 1224-1227.	2.0	4
137	Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27425.	1.5	4
138	Hydroxyurea improves cerebral oxygen saturation in children with sickle cell anemia. <i>American Journal of Hematology</i> , 2021, 96, 538-544.	4.1	4
139	Modelâ€ informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S52-S59.	2.0	4
140	Increased Vancomycin Exposure and Nephrotoxicity in Children: Therapeutic Does Not Mean Safe. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2016, 5, 65-67.	1.3	3
141	Next Challenge From the Variance in Individual Physiologicallyâ€ Based Pharmacokinetic Modelâ€ Predicted to Observed Morphine Concentration in Critically Ill Neonates. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 319-320.	4.7	3
142	Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 547-554.	2.0	3
143	Toward pharmacogenetic SLCO1B1â€ guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model. <i>Clinical and Translational Science</i> , 2021, 14, 2267-2277.	3.1	3
144	Hydroxyurea Exposure in Lactationâ€ a Pharmacokinetics Study (HELPS). <i>Blood</i> , 2018, 132, 3677-3677.	1.4	3

#	ARTICLE	IF	CITATIONS
145	Precision Dosing of Alemtuzumab: Population Pharmacokinetic Modeling in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Non-Malignant Diseases. <i>Blood</i> , 2016, 128, 2203-2203.	1.4	3
146	Therapeutic Drug Monitoring in the Era of Precision Medicine. <i>Therapeutic Drug Monitoring</i> , 2021, Publish Ahead of Print, 719-727.	2.0	3
147	Test Dose Pharmacokinetics to Predict Melphalan Dosing in Children Undergoing Hematopoietic Stem Cell Transplant (HSCT) with Organ Impairment†. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S228.	2.0	2
148	Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients. <i>Pharmacotherapy</i> , 2019, 39, 564-575.	2.6	2
149	Pediatric Phase II Study of Maraviroc for Acute Graft Versus Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S251-S252.	2.0	2
150	From Molecule to Patient and Ways to Get the Dose Precisely Right. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 534-537.	4.7	2
151	Hydromorphone population pharmacokinetics in pediatric surgical patients. <i>Paediatric Anaesthesia</i> , 2020, 30, 1091-1101.	1.1	2
152	Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study. <i>Blood</i> , 2016, 128, 3652-3652.	1.4	2
153	Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1410-1412.	2.4	1
154	P212 - PBPK modeling and simulation of morphine in virtual neonates generated using actual patient information. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, S86-S87.	2.2	1
155	Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia. <i>Blood</i> , 2018, 132, 507-507.	1.4	1
156	V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia. <i>Blood</i> , 2019, 134, 3830-3830.	1.4	1
157	Population Pharmacokinetics (PPK) of Plazomicin and Use of Therapeutic Drug Management (TDM) in Critically Ill Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
158	13 REFINED POPULATION PHARMACOKINETIC MODEL FOR INFLIXIMAB PRECISION DOSING IN PEDIATRIC INFLAMMATORY BOWEL DISEASE. <i>Gastroenterology</i> , 2018, 154, S83.	1.3	0
159	235 “ Early Infliximab Pharmacokinetics and Week One Clinical Response in Pediatric Acute Severe Ulcerative Colitis: the Arch Study. <i>Gastroenterology</i> , 2019, 156, S-44.	1.3	0
160	1543. Ceftaroline Model-based Dose Individualization in an Infant with Kidney Disease and Mediastinitis. <i>Open Forum Infectious Diseases</i> , 2019, 6, S563-S563.	0.9	0
161	1160 REAL-WORLD PEDIATRIC INFLIXIMAB PHARMACOKINETIC MODEL VERIFIES CRITICAL NEED FOR PRECISION DOSING SOFTWARE. <i>Gastroenterology</i> , 2020, 158, S-233-S-234.	1.3	0
162	Mo1895 POPULATION PHARMACOKINETIC BAYESIAN ESTIMATES AND VEDOLIZUMAB INDUCTION EXPOSURE PREDICT 1-YEAR STEROID-FREE CLINICAL REMISSION IN PEDIATRIC IBD. <i>Gastroenterology</i> , 2020, 158, S-967-S-968.	1.3	0

#	ARTICLE	IF	CITATIONS
163	613 ANTIBODIES TO INFLIXIMAB ACCELERATE DRUG CLEARANCE WHILE INTENSIFICATION STRATEGIES REVERSE IMMUNOGENICITY AND RECAPTURE CLINICAL RESPONSE. <i>Gastroenterology</i> , 2020, 158, S-130-S-131.	1.3	0
164	Alemtuzumab Precision Dosing in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S150.	2.0	0
165	Roger W. Jelliffe, MD, FCP, FAAPS. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 22-24.	4.7	0
166	Pharmacokinetics-Based Individualized Dosing Strategy to Predict Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia. <i>Blood</i> , 2015, 126, 982-982.	1.4	0
167	Characterizing important determinants of Tacrolimus pharmacokinetic variability in renal transplant patients: PBPK modeling approach using genotyped patients information. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, OR22-3.	0.0	0
168	Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption. <i>Blood</i> , 2019, 134, 4893-4893.	1.4	0
169	Pharmacokinetics of L-Glutamine (Endari) in Pediatric and Adult Sickle Cell Disease Patients: A Phase 4, Open-Label, Single-Center Study. <i>Blood</i> , 2021, 138, 980-980.	1.4	0